Literature DB >> 9584218

A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity.

S Lobert1, J W Ingram, B T Hill, J J Correia.   

Abstract

We present a comparison of the energetics of spiral formation for two vinca alkaloids: a novel difluorinated vinorelbine derivative 20',20'-difluoro-3',4'-dihydrovinorelbine (F12158, or vinflunine) and the parent compound, vinorelbine. Vinca alkaloids are antineoplastic agents that halt cell division at metaphase by inhibiting microtubule assembly and inducing tubulin self-association into spiral aggregates. The overall affinities for tubulin of vincristine, vinblastine, and vinorelbine seem to correlate with their clinical doses, where vincristine with the highest overall affinity is used at the lowest doses. Doses of chemotherapeutic agents, however, also are determined by toxicities. In the physicochemical study described here, we used sedimentation velocity to compare vinorelbine- and vinflunine-induced self-association of porcine brain tubulin in the presence of 50 micro M GDP or 50 micro M GTP. Vinflunine demonstrates 3-16-fold lower overall affinity for tubulin and induces smaller polymers compared with vinorelbine. Sedimentation velocity provides the only direct evidence to date that vinflunine is a tubulin-binding drug. Stopped-flow light scattering demonstrates the shortest relaxation times for polymer redistribution for vinflunine consistent with induction of the shortest spirals. Data collected at 5 degrees, 15 degrees, 25 degrees, and 37 degrees show increasing 20,w values with increasing temperature and are consistent with an entropically driven process. These data are entirely consistent with our hypothesis that vinflunine is likely to result in reduced clinical neurotoxicity relative to vinorelbine, vinblastine, and vincristine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9584218

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  14 in total

1.  Analytical ultracentrifugation as a contemporary biomolecular research tool.

Authors:  J L Cole; J C Hansen
Journal:  J Biomol Tech       Date:  1999-12

Review 2.  Vinflunine.

Authors:  James E Frampton; Marit D Moen
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

3.  Murine leukemia P388 vinorelbine-resistant cell lines are sensitive to vinflunine.

Authors:  Ashish Aggarwal; Anna Kruczynski; Anthony Frankfurter; John J Correia; Sharon Lobert
Journal:  Invest New Drugs       Date:  2007-12-11       Impact factor: 3.850

4.  The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively.

Authors:  Daniel M Klotz; Scott A Nelson; Karin Kroboth; Ian P Newton; Sorina Radulescu; Rachel A Ridgway; Owen J Sansom; Paul L Appleton; Inke S Näthke
Journal:  J Cell Sci       Date:  2012-03-07       Impact factor: 5.285

5.  Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks.

Authors:  Peter Johnson; Thomas Geldart; Pierre Fumoleau; Marie-Claire Pinel; Laurent Nguyen; Ian Judson
Journal:  Invest New Drugs       Date:  2006-05       Impact factor: 3.651

6.  Vinflunine -- an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study.

Authors:  J Bennouna; J-L Breton; J-M Tourani; C Ottensmeier; M O'Brien; P Kosmidis; T E Huat; M-C Pinel; C Colin; J-Y Douillard
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

7.  Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy.

Authors:  M Campone; H Cortes-Funes; D Vorobiof; M Martin; C F Slabber; E Ciruelos; E Bourbouloux; C Mendiola; F M Delgado; C Colin; V Aslanis; P Fumoleau
Journal:  Br J Cancer       Date:  2006-10-10       Impact factor: 7.640

8.  Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development.

Authors:  A Kruczynski; C Etiévant; D Perrin; N Chansard; A Duflos; B T Hill
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

9.  Vinflunine in the treatment of bladder cancer.

Authors:  Mark Bachner; Maria De Santis
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

10.  Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro.

Authors:  Cindy Simoens; Filip Lardon; Bea Pauwels; Christel M J De Pooter; Hilde A J Lambrechts; Greet G O Pattyn; Fabienne Breillout; Jan B Vermorken
Journal:  BMC Cancer       Date:  2008-02-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.